ADMA Biologics launches AI program ADMAlytics, automates plasma pooling in first commercial batch

ADMA BIOLOGICS, INC.

ADMAlytics combines generative AI and machine learning to optimize production processes.
First successful commercial use: automated plasma pooling for ASCENIV production.
Broader implementation across supply chain and operations expected to yield efficiencies.
CEO Adam Grossman says ADMAlytics supports earnings growth trajectory and continuity of patient care.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.